Fisher's Q3 Revenues Grow 13 Percent as Profit More Than Doubles
Fisher Scientific last week reported a 13-percent increase in revenues, and more than doubled its net income for the three months ended Sept. 30.
Fisher's revenues for the third quarter rose to $1.4 billion from $1.26 billion in the same period a year ago.
Net income also surged to $94 million, or $0.77 per basic share, from $36 milllion, or $0.36 per basic share in the year-ago period.
Fisher Scientific had approximately $189.2 million in cash and cash investments as of Sept. 30.
The company did not report R&D expenditures for the quarter.
In September, Fisher acquired HCS shop Cellomics for $49 million (see CBA News, 9/12/2005).
Evotec Tech Sees Losses Increase by
43 Percent amid 54-Percent Revenue Growth
Evotec Technologies, the technology division of Evotec OAI, last week reported a 54-percent growth in third-party revenue, but saw its net losses increase by 43 percent for the third quarter ended Sept. 30.
Evotec Tech's third-party revenues for Q3 rose to €3.96 million ($4.64 million), from €2.58 million in the year-ago period.
The division posted a net loss of €1.95 million in Q3, compared to €1.37 million in Q3 2004. The Tech division spent €1.5 million on R&D in Q3, on par with the amount it spent in the same quarter last year.
Evotec Tech is a subsidiary of German drug-discovery firm Evotec OAI, and counts the Opera confocal plate reader and EVOScreen integrated high-throughput screening platform among its offerings.